Article
Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy.
Journal of viral hepatitis - 1 May 2016
Velay A, Jeulin H, Eschlimann M, Malvé B, Goehringer F, Bensenane M, Frippiat J-P, Abraham P, Ismail A M, Murray J M, Combet C, Zoulim F, Bronowicki J-P, Schvoerer E
Abstract excerpt
For hepatitis B virus (HBV)-related chronic infection under treatment by nucleos(t)ide analogues (NUCs), HBsAg clearance is the ultimate therapeutic goal but very infrequent. We investigated how HBV envelope protein variability could lead to differential HBsAg clearance on NUCs. For 12 HBV genotype D patients receiving NUCs, six resolvers (HBsAg clearance) were compared to six matched nonresolvers (HBsAg...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
